Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDXEN5)

Drug Name
ZED1227 Drug Info
Synonyms
ZED-1227; 1542132-88-6; T4SR539YKF; ZED1227; CHEMBL4081588; (2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; GLUTAMINASE; UNII-T4SR539YKF; SCHEMBL16735736; SCHEMBL16751074; EX-A7845R; GTPL12802; TAK-227; BDBM50245478; AKOS040742843; HY-19359; MS-29784; CS-0015432
Indication
Disease Entry ICD 11 Status REF
Coeliac disease DA95 Phase 2 [1]
Non-alcoholic fatty liver disease DB92 Phase 2 [2]
Cross-matching ID
PubChem CID
72950407
TTD Drug ID
DMDXEN5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tissue transglutaminase (TG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID26560530-Compound-13 DMKF26Z N. A. N. A. Patented [4]
PMID26560530-Compound-54 DM2X4R0 N. A. N. A. Patented [4]
Triazole derivative 1 DM9QB2S N. A. N. A. Patented [4]
Acyl piperidine derivative 3 DMIDUB4 N. A. N. A. Patented [4]
PMID26560530-Compound-14 DM52MIK N. A. N. A. Patented [4]
PMID26560530-Compound-1 DMSI7F2 N. A. N. A. Patented [4]
PMID26560530-Compound-3 DM92OT0 N. A. N. A. Patented [4]
PMID26560530-Compound-11 DMZ5UST N. A. N. A. Patented [4]
Chloroacetyl ester derivative 1 DMW4J0P N. A. N. A. Patented [4]
PMID26560530-Compound-7 DMRAXD1 N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue transglutaminase (TG2) TT2F4OL TGM2_HUMAN Inhibitor [3]

References

1 Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022 May 17;11(10):1667.
2 ClinicalTrials.gov (NCT05305599) Double-blind, Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of ZED1227 Capsules With Placebo in the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) With Significant Fibrosis. U.S.National Institutes of Health.
3 Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022 May 17;11(10):1667.
4 Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.